Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Most Shorted Stocks
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Investors
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
MCP for Agents
Advertise with Us
Top Online Brokers
Gold IRA Companies
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Most Shorted Stocks
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Center
Investors
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Gold IRA Review
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
ATHE
Stock Latest News
Company Announcements
Alterity Therapeutics Secures FDA Pathway and Bolsters Funding for ATH434 Phase 3 in MSA
3d ago
6K
ATHE
Premium
Company Announcements
Alterity Therapeutics Files Form 6-K and Seeks Quotation for ATH Securities
12d ago
6K
ATHE
Premium
Company Announcements
Alterity Therapeutics CEO to Engage U.S. Investors at BTIG Biotechnology Conference 2026
12d ago
6K
ATHE
Premium
The Fly
Alterity Therapeutics receives FDA meeting minutes on pathway for ATH434
26d ago
ATHE
Premium
Company Announcements
Alterity Therapeutics Secures FDA-Confirmed Registrational Pathway for ATH434 in Multiple System Atrophy
26d ago
6K
ATHE
Premium
Company Announcements
Alterity Therapeutics Files July Form 6-K for Quotation of ATH Securities
1M ago
6K
ATHE
Premium
Company Announcements
Alterity Therapeutics Discloses Change in Substantial Shareholding in June 2026 SEC Filing
1M ago
6K
ATHE
Premium
The Fly
Alterity Therapeutics initiated with a Buy at JonesResearch
1M ago
ATHE
Premium
Company Announcements
Alterity Therapeutics Files June 2026 Form 6-K Highlighting Changes in Directors’ Interests
2M ago
6K
ATHE
Premium
The Fly
Alterity Therapeutics assumed with a Buy at Ladenburg
2M ago
ATHE
Premium
Company Announcements
Alterity Therapeutics Files June 2026 Corporate Presentation With U.S. Regulator
2M ago
6K
ATHE
Premium
Company Announcements
Alterity Therapeutics Files Form 6-K on Unquoted Securities Notification
2M ago
6K
ATHE
Premium
Company Announcements
Alterity Therapeutics Files June Form 6-K Highlighting Cessation of Certain Securities
2M ago
6K
ATHE
Premium
Company Announcements
Alterity Therapeutics Completes 50-for-1 Capital Consolidation After Shareholder Approval
2M ago
6K
ATHE
Premium
The Fly
Alterity Therapeutics achieves alignment with FDA on program for ATH434 in MSA
2M ago
ATHE
Premium
Company Announcements
Alterity Therapeutics Wins FDA Backing for Pivotal Phase 3 Program of ATH434 in Multiple System Atrophy
2M ago
6K
ATHE
Premium
The Fly
Alterity Therapeutics management to meet with BTIG
2M ago
ATHE
Premium
Company Announcements
Alterity Therapeutics Data Underpin Phase 3 Advancement of ATH434 in Multiple System Atrophy
3M ago
6K
ATHE
Premium
Company Announcements
Alterity Therapeutics Files May 2026 Form 6-K, Releases New Corporate Presentation
3M ago
6K
ATHE
Premium
The Fly
Alterity Therapeutics publishes quantitative susceptibility mapping MRI data
3M ago
ATHE
Premium
Company Announcements
Alterity Therapeutics Highlights MRI Biomarker Breakthrough as It Prepares Phase 3 MSA Program
3M ago
6K
ATHE
Premium
The Fly
Alterity Therapeutics receives FDA feedback after second ATH434 Type C meeting
3M ago
ATHE
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
